Logo

The real-world use of OPSUMIT® (macitentan) has been rigorously examined in both the OPUS registry and the OrPHeUS cohort study. These data demonstrate the effective use of OPSUMIT® in a broad range of patients with pulmonary arterial hypertension (PAH), including those with PAH associated with connective tissue disease (CTD), as well as in elderly patients with PAH and those with comorbidities.[1][2][3][4][5]

Component not published? componentType is undefined.

Real-world use of OPSUMIT® in patients with CTD-PAH

Real-world data from OPUS and OrPHeUS support the use of OPSUMIT® in patients with connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH) and its subtypes, including PAH associated with scleroderma/systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). Similar clinical outcomes were observed in patients with CTD-PAH and those with idiopathic PAH (IPAH)/heritable PAH (HPAH) at 2 years.[2]

patient survival at 24 months following opsumit initiation

Adapted from McLaughlin et al. 2019[2]

Real-world use of OPSUMIT® in PAH patients with comorbidities

Real-world data from the OPUS registry show that OPSUMIT® can be used effectively in patients with pulmonary arterial hypertension (PAH) and various comorbidities that may complicate treatment choice, including:[3][4]

  • Obesity
  • Diabetes mellitus
  • Hypertension
  • Anaemia*
  • Renal insufficiency

Component not published? componentType is undefined.

Real-world use of OPSUMIT® in elderly patients with PAH

Evidence from the combined OPUS registry and OrPHeUS cohort show that OPSUMIT® can be used effectively in both younger (<65 years) and older (≥65 years) patients with pulmonary arterial hypertension (PAH).*[5]

Component not published? componentType is undefined.

Continue reading

Component not published? componentType is undefined.

Component not published? componentType is undefined.

Component not published? componentType is undefined.

0

CHD, congenital heart disease; CI, confidence interval; CTD, connective tissue disease; FC, functional class; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; MCTD, mixed connective tissue disease; PAH, pulmonary arterial hypertension; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; WHO, World Health Organization

OPSUMIT® PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING

Références

Channick R et al. Presented at International Society for Heart and Lung Transplantation 39th Annual Meeting and Scientific Sessions; 3–6 April 2019; Orlando, FL, USA (Poster no. 1235).
McLaughlin VV et al. Oral presentation at CHEST Annual Meeting; 19–23 October 2019; New Orleans, LA, USA.
McLaughlin VV et al. Presented at International Society for Pharmacoeconomics and Outcomes Research Conference; 19–23 May 2018; Baltimore, MD, USA.
Rajagopal S et al. Presented online at American College of Cardiology Virtual Meeting; 28–30 March 2020 (Poster no. 1255-053).
Chin K et al. Presented at CHEST Annual Meeting; 19–23 October 2019; New Orleans, LA, USA.